Abstract: The present invention provides an anti-bacterial peptide which has anti-fungal and anti-bacterial effect. The anti-bacterial peptide is a novel peptide sequence, wherein the peptide sequence comprises a sequence of at least two SEQ ID NO: 1. The present invention also provides a method for treating a subject infected with a fungus and a bacterium, which comprises providing the subject with an anti-bacterial peptide, wherein the anti-bacterial peptide comprises a sequence of at least two SEQ ID NO: 1.

Abstract: The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.

Abstract: The present invention relates to a peptide, more particularly to a peptide comprising D-amino acids, and compositions containing the peptide, which are suitable for the treatment of IL-related diseases and conditions.

Abstract: Disclosed are fusion polypeptides comprising fragments from a first and a second isoform of an interferon lambda family, nucleic acids encoding the fusion polypeptides, and vectors and host cells containing the same, and methods of making and using such compositions in treatment of interferon lambda-related diseases, disorders, and conditions.

Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake

Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Abstract: The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.

Abstract: Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.

Abstract: The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC).

Abstract: Provided are extracellular matrix protein 1 (ECM1) and fusion protein Fc-ECM1 of the ECM1 and the Fc sequence, and also provided are cloning construction and expression of the protein, and use of the protein in preparing a pharmaceutical composition for treating multiple sclerosis.

Abstract: The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Abstract: Methods and compositions to control the stability of proteins with special emphasis on antibodies and proteins with antibody-like structures, e.g., having an “immunoglobulin-like” fold, are described. Controlling the stability facilitates different applications for a protein with the same function, but different stability.

Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.

Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Abstract: There is disclosed compositions and methods relating to or derived from anti-LAG3 antibodies. More specifically, there is disclosed fully human antibodies that bind LAG3, LAG3-antibody binding fragments and derivatives of such antibodies, and LAG3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

Abstract: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises a bispecific antibody (bsAb). Most preferably, the bsAb is an anti-CD3×anti-CD19 bispecific antibody, although antibodies against other T-cell antigens and/or disease-associated antigens may be used. The complex is capable of targeting effector T cells to induce T-cell-mediated cytotoxicity of cells associated with a disease, such as cancer, autoimmune disease or infectious disease. The cytotoxic immune response is enhanced by co-administration of interferon-based agents that comprise interferon-?, interferon-?, interferon-?1, interferon-?2 or interferon-?3.

Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).

Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

Abstract: The blood-brain barrier (BBB) prevents transport of molecules larger than 500 Dal tons from blood to brain. Receptor-mediated transcytosis (RMT) facilitates transport across the BBB of specific molecules that bind receptors on brain endothelial cells that form the BBB. An insulin-like growth factor 1 receptor (IGF 1R)-binding antibody or fragment thereof is identified that transmigrates the BBB by RMT. The antibody or fragment is used to deliver a cargo molecule across the BBB, wherein the cargo molecule may be a therapeutic or detectable agent. The antibody is a camelid VHH, prepared by immunizing a llama with a 933-amino acid IGF 1R polypeptide. Humanized forms of the camelid VHH are also generated.

Abstract: A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like.

Abstract: The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist.

Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

Abstract: Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.

Abstract: This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.

Abstract: Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.

Abstract: Methods and compositions relating to use of CRTAM agonists are provided. In some embodiments, the present invention provides methods and compositions relating to use of CRTAM in the treatment of cancer, including enhancing the efficacy of antibody therapy directed to cancer cells.

Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.

Abstract: The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.

Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.

Abstract: Multispecific antibody analogs that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), said analogs comprising a common light chain, are provided, as well as methods for their production and use.

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

Abstract: The present invention relates to a downstream industrial method of purifying chondroitin sulphate obtained from animal cartilage, which produces a product fully compliant with the specifications required for the use of said compound in the pharmaceutical field.

Abstract: The invention relates to a method for the synthesis of a novel diene polymer with a high content of phosphorus-based functions by radical grafting of a polyphosphorus-based polymer bearing a chain-end thiol function onto a diene polymer according to the following steps: a) bringing together, with stirring, at least one diene polymer in solution and at least one polyphosphorus-based polymer bearing a chain-end thiol function in solution, b) heating the homogeneous reaction mixture obtained in the previous step to the grafting reaction temperature, and c) adding the radical initiator concomitantly with either of steps a) and b) or once the grafting reaction temperature has been reached.

Abstract: Disclosed are an end-modified conjugated diene-based polymer configured such that the end of a conjugated diene-based polymer is coupled with an aminosilane-based end modifier, and a method of preparing the same.

Abstract: Disclosed are a modified conjugated diene-based polymer represented by a specific Chemical Formula and a method of preparing the same.

Abstract: A system and method for discharging a transfer slurry from a first polymerization reactor through a transfer line to a second polymerization reactor, the transfer slurry including at least diluent and a first polyethylene. A product slurry is discharged from the second polymerization reactor, the product slurry including at least diluent, the first polyethylene, and a second polyethylene. The velocity, pressure drop, or pressure loss due to friction in the transfer line is determined, and a process variable adjusted in response to the velocity, pressure drop, or pressure loss not satisfying a specified value.

Abstract: The present invention includes a first raw material feeding unit, a second raw material feeding unit, a reactor unit, and a controller configured to control the amount of a first raw material being fed from the first raw material feeding unit to the reactor unit, the amount of a second raw material being fed from the second raw material feeding unit to the reactor unit, the temperature of the first raw material being fed from the first raw material feeding unit to the reactor unit, and the temperature of the second raw material being fed from the second raw material feeding unit to the reactor unit. The first raw material is raw material monomer solution containing a raw material monomer. The second raw material is polymerization initiator solution containing a polymerization initiator. A reaction product is polymer compound resulting from a living anionic polymerization reaction of the raw material monomer.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer to form a reactive polymer, and (ii) reacting the reactive polymer with an imine compound containing a protected thiol group

Abstract: Provided are a vinylcyclopropane that exhibits volume expansion upon homopolymerization and that enables improved solvent solubility, a monomer composition that contains the vinylcyclopropane, a polymer of the vinylcyclopropane, a polymer composition that contains the polymer, and an article that is obtainable through curing of the monomer composition. The vinylcyclopropane is represented by general formula (I) shown below.

Abstract: The present technology relates to a process for polymerizing or copolymerizing ethylenically unsaturated monomers in the presence of free-radical polymerization initiators, wherein the polymerization is carried out in a continuously operated tubular reactor at temperatures from 100° C. to 350° C. and pressures from 180 MPa to 340 MPa, with a specific reactor surface area Asp of 2 m2/(t/h) to 5.5 m2/(t/h), and the tubular reactor has a specific ratio RDsp of 0.0050 MPa?1 to 0.0069 MPa?1 and an inner surface which has a surface roughness Ra of 2 ?m or less.

Abstract: Improved Ziegler-Natta catalysts and methods of making the improved catalyst are described. The Ziegler-Natta catalyst is formed using a spherical MgCl2-xROH support, where R is a linear, cyclic or branched hydrocarbon unit with 1-10 carbon atoms and where ROH is an alcohol or a mixture of at least two different alcohols and where x has a range of about 1.5 to 6.0, preferably about 2.5 to 4, more preferably about 2.9 to 3.4, and even more preferably 2.95 to 3.35. The Ziegler-Natta catalyst includes a Group 4-8 transition metal and an internal donor comprising a diether compound. The catalyst has improved activity in olefin polymerization reactions as well as good stereoregularity and hydrogen sensitivity, and may be useful in the production of phthalate-free propylene polymers having a molecular weight distribution (PI(GPC)) in the range from about 5.75 to about 9.

Abstract: A method for making a solid catalyst component for use in a Ziegler-Natta catalyst includes combining in a hydrocarbon solvent a porous particulate support with a hydrocarbon soluble organomagnesium compound to form a suspension. The organomagnesium compound is halogenated followed by addition of an alcohol and the mixture is then reacted with a titanium compound followed by a reaction with at least one diether compound to form the solid catalyst component. Afterwards the reaction product is extracted with a mixture of a titanium compound and a hydrocarbon solvent. The solid catalyst component recovered is combined with an aluminum cocatalyst to form a Ziegler-Natta catalyst system for the polymerization of olefins. In particular, the catalyst system including a diether internal electron donor may have an activity and hydrogen response suitable for the production of propylene polymers having a molecular weight distribution (PI(GPC)) in the range from about 5.75 to about 9.